MS Relapse Management & Symptom Treatment
Symptomatic management is as impactful to quality of life in multiple sclerosis (MS) as the choice of disease-modifying therapy. A comprehensive approach integrates acute relapse treatment, ongoing symptom management, wellness strategies, and multidisciplinary care. Distinguishing true relapses from pseudoexacerbations, recognizing invisible symptoms and symptom clusters, and understanding the interplay of medical comorbidities are critical skills for optimizing day-to-day function in people living with MS.
Bottom Line
- Relapse treatment: High-dose IV methylprednisolone (1 g/day for 3–5 days) is first-line; ACTH and plasma exchange are alternatives for steroid-refractory relapses
- Pseudoexacerbation: Reemergence of prior symptoms triggered by infection (especially UTI), heat, stress, or medical illness — not new CNS inflammation; treat the underlying trigger
- Dalfampridine: The only therapy FDA-approved specifically to improve walking in MS; also has emerging evidence for cognition, fatigue, depression, and eye movement abnormalities
- Fatigue: The most common MS symptom; best managed with exercise, sleep optimization, and treating comorbidities first; amantadine/modafinil/methylphenidate were no better than placebo in a rigorous crossover RCT
- Spasticity: Stretching and physical therapy are foundational; baclofen, tizanidine, and gabapentin are commonly used despite limited evidence; onabotulinumtoxinA avoids systemic CNS side effects
- Wellness foundation: Exercise (≥150 min/week), healthy nutrition, smoking cessation, and emotional well-being practices form the base of symptom self-management
Acute Relapse Management
Defining a Relapse
An MS relapse (exacerbation) is defined as new or worsening neurologic symptoms attributable to CNS demyelination lasting at least 24 hours, occurring in the absence of fever or infection, and separated from a previous attack by at least 30 days. Symptoms are generally new in character or of greater intensity than previous episodes, suggesting a new anatomical site of inflammation or re-inflammation at a previous lesion site.
Relapse vs. Pseudoexacerbation
A critical first step in evaluating any report of worsening MS symptoms is distinguishing a true relapse from a pseudoexacerbation:
| Feature | True Relapse | Pseudoexacerbation |
|---|---|---|
| Symptom character | New symptoms or greater intensity than prior | Reemergence of prior symptoms without exceeding previous severity |
| Mechanism | New CNS inflammatory demyelination | Unmasking of conduction block in previously demyelinated pathways |
| MRI | New or enlarging T2 lesions, gadolinium enhancement | Stable MRI without new activity |
| Common triggers | Not applicable (immune-mediated event) | UTI, upper respiratory infection, heat/fever, stress, overexertion, medical procedures |
| Treatment | High-dose corticosteroids | Identify and treat the underlying trigger |
Key Clinical Pearl
- Because urinary tract infections are common culprits for pseudoexacerbations, a urine dipstick with reflex culture is the minimum evaluation for all patients presenting with acute or worsening MS symptoms
- Patients with greater MS disability are particularly prone to pseudoexacerbations due to higher rates of UTI, urinary retention, constipation, and pressure sores
Acute Relapse Treatment
| Treatment | Regimen | Notes |
|---|---|---|
| IV methylprednisolone | 1 g/day for 3–5 days | First-line therapy; accelerates recovery but may not change ultimate degree of recovery |
| Oral high-dose prednisone | 1250 mg every other day for 5 doses | Bioequivalent to IV; reasonable alternative when IV access is unavailable |
| ACTH (repository corticotropin) | 80 units IM/SC daily for 5 days | Alternative for patients unable to tolerate or access IV steroids |
| Plasma exchange (PLEX) | 5–7 exchanges over 10–14 days | Reserved for severe, steroid-refractory relapses; most effective for acute, severe attacks |
Not all relapses require treatment. Mild sensory relapses that do not impair function may be observed. Treatment decisions should weigh the severity of symptoms, functional impact, and risks of corticosteroid therapy. For relapse recovery, physical and occupational therapy referrals should complement pharmacologic treatment.
Approach to Symptom Management
Framework
A stepped approach to MS symptom management begins with healthy lifestyle practices as the foundation and adds nonpharmacologic, pharmacologic, and procedural therapies as needed, balancing levels of evidence, risks, and potential benefits:
Stepped Approach to MS Symptoms
- Step 1 — Education and wellness: Explain symptom origins, support healthy lifestyles, reinforce self-management
- Step 2 — Nonpharmacologic interventions: Physical therapy, occupational therapy, cognitive rehabilitation, counseling, acupuncture, cooling strategies
- Step 3 — Pharmacologic therapy: Favor high-evidence medications; “start low, go slow”; select agents that address multiple symptoms when possible
- Step 4 — Procedural interventions: OnabotulinumtoxinA injections, intrathecal baclofen, nerve stimulators — may have a more favorable risk-benefit profile than systemic medications
A “top 3” approach helps prioritize symptoms at each visit. Frequent reevaluation is essential as symptoms fluctuate over the lifespan.
Key Considerations
- Invisible symptoms: Fatigue, cognitive impairment, depression, pain, bladder dysfunction, and sexual dysfunction are often underreported; use targeted screening questionnaires and patient-reported outcome measures
- Symptom clusters: MS symptoms occur in clusters due to common neuroanatomic origins (e.g., spinal cord lesion → spasticity + bladder dysfunction + sexual dysfunction) or secondary effects (e.g., nocturia → poor sleep → fatigue → depression). Treating the root cause can improve multiple symptoms simultaneously
- Medical comorbidities: Vascular disease, depression, sleep apnea, and obesity worsen MS symptoms and accelerate disability; aggressive management of comorbidities is an essential component of symptom treatment
- Iatrogenic causes: Polypharmacy is common in MS; medication side effects can mimic new or worsening symptoms, leading to additional medications “chasing” previous side effects
Common Symptom Management
Fatigue
Fatigue is the most frequently reported MS symptom, occurring early in the disease course and persisting throughout. MS fatigue is often described as occurring in the midafternoon after a more energetic morning, in contrast to sleep-related fatigue where patients “wake up tired.”
| Intervention | Evidence Level | Details |
|---|---|---|
| Exercise | Strong | Growing evidence that regular exercise reduces MS fatigue and may improve cognition |
| Sleep optimization | Strong | Screen for sleep apnea, restless legs, nocturia; treat underlying sleep disruptions |
| Treat comorbidities | Strong | Address anemia, hypothyroidism, depression, deconditioning |
| Energy conservation | Moderate | OT referral for energy management strategies, cooling vests |
| Dalfampridine | Emerging | 10 mg every 12 hours; FDA-approved for walking; emerging data for fatigue improvement |
| Amantadine | Low | Not superior to placebo in rigorous crossover RCT (Nourbakhsh et al., 2021) |
| Modafinil/methylphenidate | Low | Not superior to placebo with higher adverse events; temper expectations |
Spasticity
Spasticity is distinguished from tonic spasms (paroxysmal dystonia): spasticity involves pain and spasms in leg muscles after immobility, while tonic spasms are brief, stereotyped unilateral contractions lasting up to 3 minutes that respond to sodium channel blockers (carbamazepine, oxcarbazepine, lacosamide).
| Treatment | Notes |
|---|---|
| Stretching and exercise | Foundation of spasticity management; yoga, tai chi, stretching guides |
| Baclofen | Most commonly prescribed; CNS side effects (sedation, cognitive impairment, imbalance); use minimum effective dose |
| Tizanidine | Alpha-2 agonist; sedation, dry mouth; monitor liver function |
| Gabapentin | Also useful for neuropathic pain; sedation and cognitive effects |
| Cannabinoids (THC:CBD 1:1) | High-quality evidence supports modest reduction in patient-reported spasticity; not FDA-approved in the US; greatest concern is cognitive impairment |
| OnabotulinumtoxinA injections | FDA-approved for limb spasticity; avoids systemic CNS effects of oral medications |
| Intrathecal baclofen pump | For severe, refractory spasticity; requires surgical implantation |
Pain
Pain in MS has multiple mechanisms and requires targeted treatment:
- Central neuropathic pain: Gabapentin, pregabalin, duloxetine, lamotrigine
- Trigeminal neuralgia/tonic spasms: Carbamazepine (first-line), oxcarbazepine, lacosamide, acetazolamide
- Musculoskeletal pain: Physical therapy, stretching, NSAIDS; consider secondary causes (meniscal tears, hip injuries from gait abnormalities)
- Headache: Per AAN headache guidelines; migraine is common in MS and may be worsened by interferon therapy
Avoid Narcotics for MS Pain
Opioids should be avoided for chronic MS pain. They worsen fatigue, constipation, and cognitive dysfunction, contribute to falls, and carry addiction risk. Nonpharmacologic approaches (acupuncture, self-management programs, TENS) and procedure-based interventions (spinal cord stimulators) are preferred for refractory cases.
Bladder Dysfunction
Bladder symptoms affect the majority of patients with MS. Initial evaluation includes postvoid residual measurement and urine culture:
- Overactive bladder (urgency/frequency): Antimuscarinics (oxybutynin, tolterodine, solifenacin, darifenacin, trospium) or β3-adrenergic agonist (mirabegron); trospium and darifenacin may have fewer cognitive effects due to less blood-brain barrier penetration
- Urinary retention (PVR >100 mL): Intermittent self-catheterization
- OnabotulinumtoxinA bladder injections: Efficacy lasting up to 9 months; FDA-approved for neurogenic bladder and urinary incontinence
- Lifestyle: Pelvic floor exercises, avoid bladder irritants (caffeine, tobacco, alcohol), scheduled voiding, fluid management
Cognitive Impairment
Cognitive dysfunction affects 40–65% of patients with MS, primarily impacting information processing speed, episodic memory, and executive function. Screening tools include the Symbol Digit Modalities Test (SDMT), which is sensitive, brief, and repeatable. Management includes:
- Regular exercise and social engagement
- Neuropsychological testing for baseline and monitoring
- Speech/cognitive therapy for compensatory strategies
- Dalfampridine (emerging evidence for cognitive benefit)
- Minimize medications with cognitive side effects (anticholinergics, benzodiazepines, muscle relaxants, cannabis)
- Aggressive management of depression, fatigue, and sleep disorders
Depression and Mood
Depression is highly prevalent in MS and contributes to worse quality of life, cognitive impairment, and reduced treatment adherence. SSRIs and SNRIs are first-line pharmacotherapy. Cognitive-behavioral therapy is effective. Pseudobulbar affect (pathologic laughing or crying disproportionate to context) occurs in approximately 10% of MS cases and is treated with dextromethorphan/quinidine.
Walking and Mobility
Dalfampridine (4-aminopyridine) is the only FDA-approved symptomatic therapy specifically for MS, indicated to improve walking speed. A potassium channel blocker, it enhances conduction in demyelinated pathways. Key considerations:
- Dose: 10 mg every 12 hours (extended-release)
- Additional benefits: walking duration, finger dexterity, cognitive function (SDMT), and emerging data for fatigue, depression, and eye movement abnormalities (INO, nystagmus)
- Contraindications: seizure history, creatinine clearance ≤50 mL/min
- Consider periodic drug holidays (2 weeks) in older patients to reassess efficacy and emergent side effects, as creatinine clearance decreases with age
Wellness and Lifestyle
Exercise
Updated expert recommendations (2020) support exercise across the full spectrum of MS disability:
| Disability Level (EDSS) | Recommendations |
|---|---|
| Mild (0–4.5) | Aerobic 2–3×/week (walking, cycling, swimming); resistance 2–3×/week; daily stretching; neuromotor exercises (Pilates, yoga, tai chi) 3–6×/week |
| Moderate (5.0–6.5) | Same as mild with adaptations: recumbent bicycle, pole-walking, cooling strategies |
| Severe (7.0–8.5) | Up to 10–20 min/day; breathing exercises, flexibility, upper extremity exercises, seated balance work |
| Very severe (9.0) | Up to 10 min/day; passive range of motion, breathing exercises, functional electrical stimulation |
Recommended weekly exercise time is at least 150 minutes. Verbal recommendations from physicians are more effective at promoting behavioral change than printed materials alone.
Nutrition
No single diet has been proven best for MS, but commonalities across dietary interventions that improve MS symptoms include increased fruits and vegetables, reduced processed foods and refined sugars, and whole grains over refined grains. Evidence supports several approaches:
- Modified Mediterranean diet: RCT data showing improvement in fatigue and general MS symptoms
- Calorie restriction/intermittent fasting: Improved fatigue, depression, quality of life; time-restricted feeding had better adherence than calorie restriction
- Modified Paleolithic diet: Improved fatigue, cognition, hand dexterity; did not cause nutritional deficits
- Vitamin D supplementation: 2,000–4,000 IU daily to maintain 25(OH)D at 40–60 ng/mL; observational associations with lower relapse risk; prospective RCTs have not confirmed disease-modifying benefit
Smoking Cessation
Smoking is associated with higher risk of acquiring MS, faster disability progression, and increased risk of conversion to SPMS. Modification of disability following smoking cessation has been documented, supporting that it is never “too late” for a patient with MS to quit smoking.
Special Considerations
Dietary Supplements
Up to 80% of patients with MS use nonprescription dietary supplements. Unlike FDA-approved medications, supplements do not require safety or efficacy testing before marketing. Notable safety concerns identified through clinical trials include membranous nephropathy from lipoic acid and hepatotoxicity from green tea extract. Clinicians should include supplements on medication lists, conduct routine safety screening, and refer to registered dietitians when appropriate.
Cannabis and Cannabinoids
Two AAN systematic reviews concluded that high-quality evidence supports a modest reduction in patient-reported spasticity with cannabinoids (nabiximols, THC:CBD 1:1 oromucosal spray). However, the greatest concern is cognitive impairment: chronic cannabis users with MS demonstrate poorer cognitive performance, and cessation for 28 days showed improved memory, processing speed, and executive function. No cannabis-derived THC products are FDA-approved for MS in the United States.
Quality Metrics
The AAN MS Quality Measurement Set (2020 update) includes six measures, three of which address symptom management: screening for bladder/bowel/sexual dysfunction, cognitive impairment, and fatigue. A fourth pertains to exercise counseling. These serve as guidelines for comprehensive MS care.
References
- Spain R. Approach to symptom management of multiple sclerosis with a focus on wellness. Continuum (Minneap Minn). 2022;28(4):1052-1082.
- Nourbakhsh B, Revirajan N, Morris B, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol. 2021;20(1):38-48.
- Kalb R, Brown TR, Coote S, et al. Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course. Mult Scler. 2020;26(12):1459-1469.
- Rae-Grant A, Amezcua L, English JJ, et al. Quality improvement in neurology: multiple sclerosis quality measurement set 2020 update. Neurology. 2021;97(3):134-142.
- Zhang E, Tian X, Li R, et al. Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials. Orphanet J Rare Dis. 2021;16(1):87.
- Yadav V, Bever C, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis. Neurology. 2014;82:1083-1092.